//www.igerbera.com/journals/jamadermatology The Most Read articles published by JAMA Dermatology en-us Tue, 28 Mar 2023 22:43:36 GMT Tue, 28 Mar 2023 22:43:36 GMT Silverchair jamams@jamanetwork.org support@www.igerbera.com //www.igerbera.com/journals/jamadermatology/fullarticle/2793784 星期四,2022年9月1日格林尼治时间就是 This Patient Page describes the symptoms, diagnosis, and treatment of vulvar lichen sclerosus. 158 9 1088 1088 10.1001/jamadermatol.2022.0359 2793784 //www.igerbera.com/journals/jamadermatology/fullarticle/2788258 星期二,2022年3月1日00:00:00 GMT This network meta-analysis examines whether minoxidil, dutasteride, or finasteride monotherapy is the most efficacious for the treatment of male androgenetic alopecia. 158 3 266 274 10.1001/jamadermatol.2021.5743 2788258 //www.igerbera.com/journals/jamadermatology/fullarticle/2797292 Thu, 01 Dec 2022 00:00:00 GMT This Patient Page describes the symptoms, diagnosis, and treatment of sarcoidosis of the skin. 158 12 1464 1464 10.1001/jamadermatol.2022.0360 2797292 //www.igerbera.com/journals/jamadermatology/fullarticle/2801908 Wed, 08 Mar 2023 00:00:00 GMT This randomized clinical trial evaluates the efficacy and tolerance of methotrexate alone or combined with low-dose prednisone in patients with chronic and recalcitrant alopecia areata totalis or universalis. 10.1001/jamadermatol.2022.6687 2801908 //www.igerbera.com/journals/jamadermatology/fullarticle/2800236 Wed, 01 Feb 2023 00:00:00 GMT This randomized clinical trial examines the efficacy and safety of lebrikizumab in combination with background topical corticosteroid therapy in adolescents and adults with moderate-to-severe atopic dermatitis. 159 2 182 191 10.1001/jamadermatol.2022.5534 2800236 //www.igerbera.com/journals/jamadermatology/fullarticle/2801705 Wed, 01 Mar 2023 00:00:00 GMT This cohort study examines the annual prevalence and incidence of alopecia areata and alopecia totalis/alopecia universalis in the US. 10.1001/jamadermatol.2023.0002 2801705 //www.igerbera.com/journals/jamadermatology/fullarticle/2802159 Wed, 15 Mar 2023 00:00:00 GMT This consensus statement provides consensus recommendations on optimal screening practices and prebiopsy diagnostic, postbiopsy diagnostic, and prognostic assessment of cutaneous melanoma. 10.1001/jamadermatol.2023.0127 2802159 //www.igerbera.com/journals/jamadermatology/fullarticle/2782803 Wed, 01 Sep 2021 00:00:00 GMT This randomized clinical trial assesses the safety and efficacy of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis. 157 9 1047 1055 10.1001/jamadermatol.2021.3023 2782803 //www.igerbera.com/journals/jamadermatology/fullarticle/2768938 Sun, 01 Nov 2020 00:00:00 GMT This case series evaluates the clinical and dermoscopic features of vulvar melanosis and their changes over time. 156 11 1185 1191 10.1001/jamadermatol.2020.2528 2768938 //www.igerbera.com/journals/jamadermatology/fullarticle/2800880 Wed, 01 Mar 2023 00:00:00 GMT This post hoc analysis of 6 randomized, double-blind, placebo-controlled trials assesses the efficacy and safety of dupilumab in patients with erythrodermic atopic dermatitis. 159 3 255 266 10.1001/jamadermatol.2022.6192 2800880 //www.igerbera.com/journals/jamadermatology/fullarticle/2766772 Sat, 01 Aug 2020 00:00:00 GMT This randomized clinical trial investigates the efficacy and safety of abrocitinib in adolescents and adults with moderate-to-severe atopic dermatitis. 156 8 863 873 10.1001/jamadermatol.2020.1406 2766772 //www.igerbera.com/journals/jamadermatology/fullarticle/2737332 Tue, 01 Oct 2019 00:00:00 GMT This study evaluates types and frequency of psychiatric adverse events that were reported to the US Food and Drug Administration’s Adverse Event Reporting System from 1997 through 2017 for patients taking isotretinoin. 155 10 1162 1166 10.1001/jamadermatol.2019.1416 2737332 //www.igerbera.com/journals/jamadermatology/fullarticle/2802696 Fri, 17 Mar 2023 00:00:00 GMT This systematic review examines the demographic characteristics, clinical presentations, treatments, and outcomes of patients receiving tumor necrosis factor–α inhibitors (TNFis) to treat acne and patients who develop acne following treatment of other conditions with TNFis. 10.1001/jamadermatol.2023.0269 2802696 //www.igerbera.com/journals/jamadermatology/fullarticle/2801912 Wed, 08 Mar 2023 00:00:00 GMT This case report describes an ulcerated violaceous nodule on the right nasal ala as well as 3 small ulcers on the neck, back, and buttocks. 10.1001/jamadermatol.2022.5839 2801912 //www.igerbera.com/journals/jamadermatology/fullarticle/2801708 Wed, 01 Mar 2023 00:00:00 GMT A woman in her late 40s presented with a 40-year history of hard nodules on the scalp, feet, trunk, and lower extremities. What is your diagnosis? 10.1001/jamadermatol.2023.0024 2801708 //www.igerbera.com/journals/jamadermatology/fullarticle/2779643 Tue, 01 Jun 2021 00:00:00 GMT This case-series study describes the clinical course and histopathologic examination findings for delayed localized cutaneous injection-site reactions to the Moderna COVID-19 vaccine. 157 6 716 720 10.1001/jamadermatol.2021.1214 2779643 //www.igerbera.com/journals/jamadermatology/fullarticle/2767074 Sat, 01 Aug 2020 00:00:00 GMT This cohort study reports the trends and variations in skin and subcutaneous diseases, along with malignant melanoma and keratinocyte carcinoma, in the 50 states and the District of Columbia for the past 3 decades. 156 8 874 881 10.1001/jamadermatol.2020.1573 2767074 //www.igerbera.com/journals/jamadermatology/fullarticle/2801093 Wed, 15 Feb 2023 00:00:00 GMT This systematic review and meta-analysis of 38 studies including 2917 patients evaluates the prevalence of antibiotics associated with Stevens-Johnson syndrome and toxic epidermal necrolysis worldwide. 10.1001/jamadermatol.2022.6378 2801093 //www.igerbera.com/journals/jamadermatology/fullarticle/2790388 Sun, 01 May 2022 00:00:00 GMT This living systematic review and network meta-analysis examines the association of systemic treatments for atopic dermatitis with scores on the Eczema Area and Severity Index, Patient Oriented Eczema Measure, Dermatology Life Quality Index, and Peak Pruritus Numeric Rating Scales. 158 5 523 532 10.1001/jamadermatol.2022.0455 2790388 //www.igerbera.com/journals/jamadermatology/fullarticle/2801706 Wed, 01 Mar 2023 00:00:00 GMT This case report describes numerous dome-shaped, firm, yellow papules that were present symmetrically on the back, shoulder, arm, thigh, and knees. 10.1001/jamadermatol.2022.5834 2801706 //www.igerbera.com/journals/jamadermatology/fullarticle/2790344 Sun, 01 May 2022 00:00:00 GMT This epidemiological assessment uses the GLOBOCAN database to evaluate the numbers of new cases and deaths due to cutaneous melanoma globally and by world region in 2020 and to estimate global values in 2040. 158 5 495 503 10.1001/jamadermatol.2022.0160 2790344 //www.igerbera.com/journals/jamadermatology/fullarticle/2800634 Wed, 01 Mar 2023 00:00:00 GMT This mendelian randomization examines the association between genetically proxied lipid-lowering drugs and psoriasis risk. 159 3 275 280 10.1001/jamadermatol.2022.6051 2800634 //www.igerbera.com/journals/jamadermatology/fullarticle/2771625 Tue, 01 Dec 2020 00:00:00 GMT This secondary analysis of 2 randomized clinical trials compares patient-reported outcomes of treatment with risankizumab vs ustekinumab and placebo in psoriasis symptoms, health-related quality of life, and mental health among patients with moderate to severe psoriasis. 156 12 1344 1353 10.1001/jamadermatol.2020.3617 2771625 //www.igerbera.com/journals/jamadermatology/fullarticle/2767075 Sat, 01 Aug 2020 00:00:00 GMT This cross-sectional study examines the dietary patterns of adults with current acne. 156 8 854 862 10.1001/jamadermatol.2020.1602 2767075 //www.igerbera.com/journals/jamadermatology/fullarticle/2789438 Fri, 01 Apr 2022 00:00:00 GMT This analysis of 2 randomized clinical trials evaluates long-term (52 weeks) efficacy and safety of upadacitinib treatment in patients with atopic dermatitis. 158 4 404 413 10.1001/jamadermatol.2022.0029 2789438

map